Adipose-Derived Stem Cells Versus Artery Explants as Sources of Autologous Smooth Muscle for Blood Vessel Bioengineering  by Bernish, Brian W. et al.
A
m
M
D
T
y
D
t
p
t
r
o
p
h
a
h
s
c
a
a
s
c
i
a
a
a
d
A
r
a
m
A
A
B
R
S
w
o
r
o
(
o
JOURNAL OF VASCULAR SURGERY
December 20111862 AbstractsEstablishing Polymeric Transfection as a Non-Viral, Non-Toxic
Method for Gene Therapy in the Prevention of Vascular Disease
Joshua D. Arnold, Deidra J.H. Mountain, Michael B. Freeman,
Stacy S. Kirkpatrick, Scott L. Stevens, Mitchell H. Goldman,
Oscar H. Grandas, University of Tennessee Graduate School of Medicine,
Knoxville, Tenn
Objective: Gene therapy shows promise in the treatment of vascular
disease, but a formidable challenge has been delivery of genetic material in a
safe and non-toxic way. Traditional transfection methods commonly used in
the laboratory are poorly translatable in vivo, and there are currently no
FDA-approved gene therapy products for clinical application. Biodegrad-
able polymers, particularly poly(B-amino ester)s, have shown promise in
their ability to deliver genetic material to a cell in a predictable and non-toxic
way. However, the preponderance of early feasibility studies were tested and
validated exclusively in stem cells. While stem cell derived therapies are
promising in areas such as vascular tissue engineering and angiogenesis,
dysfunctional regulation in differentiated cells is the primary source of
pathogenesis. As such, gene therapy in these differentiated cell types would
be prime targets for therapeutic gene modulation in the prevention of
hyperplasia and restenosis. Here we aim to establish polymeric transfection
as a feasible non-viral, non-toxic method for gene therapy in cells of vascular
origin and in vascular tissue.
Methods: Human aortic smooth muscle cells (HASMC) were trans-
fected in vitro and rodent carotid artery segments were transfected ex vivo
with poly(-amino ester) polymers (StemFECT™) conjugated to Cy3-
labeled GAPDH or negative control (NC) siRNA. Increasing polymer:
siRNA ratios were tested for optimal transfection efficiency. At 48hrs post-
transfection a live-dead stain was performed to confirm cell/vessel viability,
conjugate endocytosis was confirmed by fluorescent microscopy, and
GAPDH gene silencing was measured by qPCR normalized to 18S.
Results: Cellular translocation of the polymeric bioconjugates in
HASMC in vitro was visible using a 0.65L polymer: 100pmol siRNA/ml
conjugate (Fig 1, A). Efficient gene silencing was achieved in a polymer
concentration dependent manner, independent of increasing siRNA con-
centrations (Fig 1, B). Themost efficient in vitro GAPDH silencing was with
a 1.95L polymer: 100pmol siRNA/ml conjugate (10  1% expression vs
NC; n  5; *P  .05 vs NC and 1.3L:100pmol conjugate). Using this
bioconjugate ratio for vessel transfection ex vivo, translocation was visible in
all cellular layers (Fig 2, B; images representative of proximal, medial, and
distal sections), and modest GAPDH silencing was observed (76  8%
expression vs NC; n  2).
Conclusions: HASMCs and whole vessel segments were successfully
transfected using polymeric bioconjugates. The significant gene silencing
accomplished here establishes our proof of concept that polymeric transfec-
tion is a viable method for in vitro and ex vivo investigation in vascular cells.
Future studies will expand on this method of gene therapy for in vivo
transfection in animal models of vascular disease. Our long term goal is to
deliver molecular inhibitors of genes thought to play a role in intimal
hyperplasia, restenosis, and vessel graft failure. Polymeric transfection may
translate to targeted genetic therapy for vascular disease.
Fig 1. l
wttenuation of Spinal Cord Ischemia-Reperfusion Injury With Treat-
ent of Alpha-2 Agonist Dexmedetomidine
arshall T. Bell, Phillip D. Smith, Joseph C. Cleveland, Jr.,
avid A. Fullerton, Xainzhong Meng, Michael J. Weyant, Ferenc Puskas,
. Brett Reece, Univeristy of Colorado, Aurora, Colo
Background:Despite surgical adjuncts, delayed lower extremity paral-
sis remains a devastating complication following thoracic aortic surgery.
exmedetomidine is a selective -2a agonist commonly used for sedation in
he critical care setting. It has been shown to have both neuronal and renal
rotective affects against ischemia-reperfusion injuries. We hypothesized
hat treatment with dexmedetomidine will attenuate spinal cord ischemia-
eperfusion injury via inhibition of microglial activation.
Methods: Adult C57bL/6 mice underwent sternotomy followed by
cclusion of the aortic arch for 4 minutes. Eight experimental mice received
retreatment with 25ìg/kg of intrapeirtoneal dexmedetomidine and at 12
our intervals following reperfusion. Eight control mice received an equiv-
lent amount of 0.9% normal saline. Functional analysis was obtained at 12
ours intervals and scored using the Basso, Beattie and Bresnahan (BBB)
core until 60 hours. All mice were euthanized at 60 hours. Their spinal
ords were removed en bloc and were stained with hematoxylin and eosin to
sses neuronal viability. Immunofluorescence staining with Iba-1marker a of
ctivated microglia was done at 12 hours after reperfusion in three mice (1
ham, 1 ischemic , control and 1 dexmedetomidine treated).
Results: Treated mice demonstrated preserved motor function as
ompared with ischemic controls (Fig 1). In addition, cyto-architecture in
schemic control mice showed decreased neuronal viability by hematoxylin
nd eosin staining. Immunofluorescence staining of spinal cords at 12 hrs
fter reperfusion with Iba-1, marker of activated microglia, shows decreased
ctivation of microglia in treatment groups.
Conclusions: Treatment of mice with alpha-2 agonist dexmedetomi-
ine preserves motor function after spinal cord ischemia- reperfusion injury.
dditionally, dexmedetomidine preserves spinal cord cyto-architecture and
educes microglia activation. In conclusion dexmedetomidine appears to
ttenuate spinal cord ischemia-reperfusion injury through inhibition of
icroglia activation.
dipose-Derived Stem Cells Versus Artery Explants as Sources of
utologous Smooth Muscle for Blood Vessel Bioengineering
rian W. Bernish, Xue Ma, Zhan Wang, Masood Machingal, Shay Soker,
andolph L. Geary, Wake Forest University School of Medicine, Winston-
alem, NC
Background: Blood vessel bioengineering holds promise for patients
ithout vein suitable for arterial reconstruction or dialysis access but the lack
f a ready source of autologous cells from which to construct new vessels
emains a limitation. We have engineered vessels for use in a pre-clinical
vine model using smooth muscle cells cultured from native artery wall
aSMC) but an artery biopsy is less practical in the clinical setting. A number
f investigators have suggested adipose-derived stem cells (ADSC) provide a
Fig 2.ess invasive alternative source of SMC but methods and results have varied
idely.
T
d
d
a
F
T
v
f
(
a
g
a

p
a
c
c
p
c
s
F
m
t
C
U
D
L
N
S
(
d
(
a
i
b
w
C
a
w
d
i
d
b
C
w
i
u
o
i
a
m
v
d
c
t
D
.
i
d
d
r
G
b
p
D
i
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 6 Abstracts 1863Methods:To determine the extent to which ovine ADSCs differentiate
into an aSMC phenotype, we compared cell morphology and growth
characteristics, expression of SMC-specific proteins, and the ability of cells to
contract type-I collagen gels. ADSC lines were established from the vascular
stromal fraction of subcutaneous fat biopsies from three individual sheep and
maintained in stem cell media or grown in SMC differentiation media (DM)
(-MEM, 1% embryonic FBS, penn/strep and L-glut)  TGF-	 (10ng/
mL). Cells were also exposed to uniaxial stretch during differentiation to
determine any additional effects on phenotype (collagen-coated Flexcell
plates, 10% strain, 60 Hz).
Results: Each ADSC isolate was first shown to be multi-potent by
growing subcultures in osteogenic or adipogenic differentiation media and
documenting typical mineralization and lipid accumulation, respectively.
ADSCmaintained in stem cell media were smaller than control aSMC, grew
to confluence one to two days faster, and expressed low levels of the SMC
markers -actin, myosin heavy chain (sm-MHC) and smoothelin. In con-
trast, after 7 days in DM, ADSC had developed morphology and growth
kinetics similar to control aSMC and showed significant up-regulation of all
protein markers. TGF- or cyclical stretch did not further enhance marker
expression compared to DM alone. Unlike control aSMC, undifferentiated
ADSC did not contract 3-dimensional collagen gels (diam. after 18 hrs: 14.6
 0.2 vs 18.0  0.0 mm, P  .001). Remarkably, ADSC grown in DM for
7 days contracted collagen gels as vigorously as control aSMCs, while the
addition of TGF-â limited contraction slightly (13.0  0.2 vs 16.8  0.2
mm, respectively, P  .002 vs both ADSC and aSMC).
Conclusions: Multi-potent ADSCs are readily obtained from subcu-
taneous fat, grow rapidly, but express low levels of SMC-specific markers at
baseline. Switching to a low-serumDM significantly shifts ADSC phenotype
toward that of control aSMC but, in contrast to previous reports, no
additional shift was seen with growth factors or mechanical stretch. These
observations support the potential for SMC-like cells differentiated from
ADSC to provide a less invasive source of autologous SMC for clinical
application of blood vessel bioengineering. Further research is needed to
determine the capacity of these cells to populate vascular scaffolds and the
fate of cells after implantation.
Characterization of the Lung Endothelial Cell Injury Response During
Ischemic Acute Kidney Injury: The Role of TNF Signaling
Laura White,1 Yan Cui,1 Rachel J. Santora,1 Carolyn M. Feltes-Shelak,2
Heitham T. Hassoun,13, 1The Methodist Hospital Department of Surgery
and Research Institute, Houston, Tex; 2Legacy Emmanuel Children’s Hos-
pital, Portland, Ore; 3The Methodist Hospital Department of Surgery and
Research Institute and The Methodist DeBakey Heart & Vascular Center,
Houston, Tex
Introduction:Despite advancements in renal replacement therapy, the
mortality rate for acute kidney injury (AKI) remains unchanged over the past
several decades, likely due to extra-renal organ dysfunction. Kidney isch-
emia-reperfusion injury (IRI) activates cellular and soluble mediators that
stimulate the innate and adaptive immune systems and incite a distinct
remote organ pulmonary pro-inflammatory and pro-apoptotic response.
Ischemic AKI induces tumor necrosis factor 1 (TNFR1)-dependent lung
apoptosis and results in lungmicrovascular barrier dysfunction in vivo. Here,
we focused on kidney-lung crosstalk at the cellular level and hypothesized
that endothelial cells (ECs), with their critical role in maintaining the
semipermeable barrier, are important targets leading to disruption of micro-
vascular permeability during ischemic AKI. In a series of parallel in vivo and
in vitro experiments, we sought to characterize the pulmonary EC-specific
transcriptional and structural response to kidney IRI and hypothesized that
TNF-/TNFR1 signaling inhibition would attenuate EC alterations during
ischemic AKI.
Methods: Male C57/BL6 mice or Sprague-Dawley rats underwent
60 minutes of bilateral kidney ischemia (IRI) or sham laparotomy (sham)
and were sacrificed at 24 hours. In mice, co-localization studies with
DAPI, TUNEL, and CD34 staining were performed, and lung microvas-
cular ECs [CD45/CD31] were isolated with novel tissue digestion
techniques followed by antibody-coupled magnetic bead sorting to 95%
purity (by flow cytometry). Isolated ECs were analyzed with Apoptosis
and EC Activation RT-PCR “SuperArrays” each containing 84 pathway-
specific genes. In parallel, rat lung microvascular ECs (RLMVECs)
grown to confluence were treated for 24 hours with serum from rats
during IRI or sham, and assays included 1) DAPI/phalloidin staining to
assess the actin cytoskeleton, 2) poly(ADP-ribose) polymerase(PARP)
activity assay to measure apoptosis, and 3) RT-PCR to quantify transcrip-
tion of TNF super-family and pro-inflammatory genes / pre-treat-
ment with Etanercept.Results: Immunofluorescence micrographs stained with DAPI,
UNEL and CD34 co-localized, suggesting lung EC apoptosis in vivo
uring ischemic AKI. Isolated lung ECs exhibited significant changes
uring ischemic AKI in prominent genes identified by “SuperArray”
nalysis, including genes related to apoptosis (Dapk1, RhoB, Bcl10,
asL, Cflar), the TNF super-family (TNF-, Tnfrsf10b[DR5],
rp53inp1, Trp63) and inflammation (E-Selectin, ICAM-1, IL-6). In
itro, RLMVECs treated with IRI serum displayed actin stress fiber
ormation and increased apoptosis at 4 and 24 hours compared to sham
0.24 0.06 vs 1.71 0.44*; 0.24 0.07 vs 1.33 0.36*). RLMVECs
lso demonstrated increased transcription of TNF super-family related
enes during IRI, and the pro-inflammatory transcriptional response was
ttenuated by TNF-/TNFR1 signaling inhibition with Etanercept. *P
.05 vs sham, n  4/group.
Conclusions: Kidney-lung crosstalk during ischemic AKI is a complex
athophysiological process involving the activation of several key cellular
nd soluble factors that drive remote organ injury. Ischemic AKI produces
hanges in the pulmonary EC phenotype with the induction of actin
ytoskeleton rearrangement, apoptosis, and a distinct pro-inflammatory and
ro-apoptotic transcriptional response. Additionally, kidney IRI drives in-
reased transcription of TNF super-family genes, and TNF-/TNFR1
ignaling inhibition attenuates the EC inflammatory response in vitro.
uture endeavors to characterize the EC-specific response and effector
echanisms to remote organ injury during ischemic AKI may reveal poten-
ial therapeutic targets for kidney-lung crosstalk.
TA-Based Anatomic Evaluation of Saphenous Vein Bypass Conduit:
tility and Correlation With Duplex Ultrasound
orian J. deFreitas,1 Timothy P. Love,1 Karthikeshwar Kasirajan,2
uke P. Brewster,1 Ravi K. Veeraswamy,1 Atef Salam,2 Joseph J Ricotta, Jr,1
oel Haskins,2 Ron Mixon,2 Matthew A Corriere,2 1Emory University
chool of Medicine, Atlanta, Ga; 2Atlanta VA Medical Center, Atlanta, Ga
Background: Lower extremity Computed Tomography Angiography
CTA) is frequently utilized for anatomic assessment of peripheral arterial
isease. In patients requiring lower extremity bypass, duplex ultrasound
DUS) is routinely obtained to evaluated great saphenous vein (GSV) for use
s conduit. GSV is visible on CTA images but not routinely assessed or
ncluded in study interpretation. We hypothesized that CTA images could
e used tomeasure GSV diameters, and that these diameters would correlate
ith DUS measurements.
Methods: Consecutive patients evaluated preoperatively with both
TA and DUS vein mapping prior to lower extremity bypass were identified
t a single hospital. All CTAs were performed using standard protocol
ithout venous phase imaging. Minimum above- and below-knee GSV
iameters were independently measured from electronically archived CTA
mages by two observers. Adequate GSV was defined as minimum DUS
iameter 3 mm. Reproducibility of CTA-based diameter measurements
etween observers was evaluated using intraclass correlation coefficients.
orrelation between CTA and DUS-based GSV diameters was evaluated
ith linear regression and Spearman correlation coefficients. Cut-points for
dentification of adequate GSV bypass conduit using CTA were determined
sing receiver operating characteristic curves.
Results: Thirty six limbs were evaluated in 27 patients. In the absence
f previous surgical removal, GSV was visible on all CTAs reviewed. No
nstances of GSV thrombosis were identified on DUS. Mean minimum
bove-knee GSV diameters were 3.8  1.3 mm for CTA versus 2.9  0.9
m forDUS;mean below-kneeGSV diameters were 2.6 0.8mm for CTA
ersus 2.5  0.9 mm for DUS. Inter-observer reproducibility of CTA
iameter measurements was excellent above-knee [intraclass correlation
oefficient (95% CI): 0.86 (0.75-0.92)] and below-knee [intraclass correla-
ion coefficient (95% CI): 0.77 (0.57-0.88)]. Correlation between CTA and
US-based GSV diameters was highly significant at both above-knee (
 
64, P  .0001) and below-knee (
  .60, P  .0017) locations (Fig). For
dentification of adequate bypass conduit using CTA, above-knee GSV
iameter 3.9 mm was 65% sensitive and 74% specific; below- knee GSV
iameter 3.0mm was 56% sensitive and 94% specific.
Conclusions: CTA-based GSV diameter measurements have excellent
eproducibility and highly significant correlation with DUS. CTA-based
SV diameter is a specific but relatively insensitive indicator of adequate
ypass conduit. When CTA-based diameters indicate inadequate GSV by-
ass conduit, confirmatory DUS vein mapping is warranted. Confirmatory
US vein mapping may be unnecessary when adequate vein diameter is
dentified on CTA.
